NHS LPP - Health and Social Care Apps DPS

Concepts

• software package
• mental health
• child health
• sexual health,category 23
• sexual health
• social care apps dps
• a health and social care applications dynamic purchasing system
• health
• social
• nhs

Location

London

Description

The original CONTRACT NOTICE (04/10/2019) 2019/s 192-45638 https://ted.europa.eu/udl?uri=TED:NOTICE:465638-2019:TEXT:EN:HTML. The DPS was initial awarded 2019 and is still open to new applications.Original short description as published in notice 2021/s 221-584062:The London Procurement Partnership is advertising for suppliers for a health and social care applications dynamic purchasing system.The purpose of this DPS will be to provide the public sector with a mechanism to procure safe and clinically beneficial applications to meet their health and social care needs supporting patients, clinicians and non-clinical staff.The initial categories covered under this DPS are:Category 1: Child health,Category 2: Diabetes and hormones,Category 3: Heart/blood vessels,Category 4: Mental health,Category 5: Pregnancy,Category 6: Brain/nerves,Category 7: Cancer,Category 8: Healthy living,Category 9: Joints/bone/muscle,Category 10: Medicines and clinical reference,Category 11: Covid-19 Support solutions,Category 12: Chest and lung,Category 13 – Blood,Category 14 – Dental,Category 15 – Ear / Nose / Throat / Mouth,Category 16 – Education,Category 17 – Eyes,Category 18 – First Aid,Category 19 – Gastrointestinal,Category 20 – Kidney / Genito-Urinary,Category 21 – Men’s Health,Category 22 – Sexual Health,Category 23 – Skin,Category 24 – Tropical Diseases,Category 25 – Woman’s Health.Please note that the categories have been split further in to subcategories (please refer to the document packfor further information).This OJEU notice is a republished notice from the original — 2019/S 192-465638.A notice was also published for categories 5-10

Ammendments to Previous Notice

CPV Codes

• 48000000 - Software package and information systems

Other Information

— 2020/S 042-100524This is an extension of the DPS with multiple supplier awards. For the list of awarded suppliers please click on the link https://healthappsdps.orcha.co.uk/DPS Extension as permitted under PCR 2015 and allowed for within the original procurement documents at the DPS initiationOriginal CONTRACT NOTICE (04/10/2019) 2019/s 192-45638 https://ted.europa.eu/udl?uri=TED:NOTICE:465638-2019:TEXT:EN:HTMLSupplement notice (25/11/2019) 2019/s 227-557047 https://ted.europa.eu/udl?uri=TED:NOTICE:557047-2019:TEXT:EN:HTMLNotice (28/02/2020) 2020/s 042-100524 https://ted.europa.eu/udl?uri=TED:NOTICE:100524-2020:TEXT:EN:HTMLNotice (27/03/2020) 2020/s 062-149867 https://ted.europa.eu/udl?uri=TED:NOTICE:149867-2020:TEXT:EN:HTMLNotice (02/06/2020) 2020/s 105-255385 https://ted.europa.eu/udl?uri=TED:NOTICE:255385-2020:TEXT:EN:HTMLNotice (15/11/2021) 2021/s 221-584062 https://ted.europa.eu/udl?uri=TED:NOTICE:584062-2021:TEXT:EN:HTML NHS London Procurement Partnership will add an additional category to the existing Health Apps DPS;Category 26 – NICE Accredited Apps An evidence-based therapeutic intervention delivered through software to prevent, manage, or treat a medical disorder or disease. They are typically accessed via a smartphone app or online and engage the patient without the involvement of a clinician.The evidence-based therapeutic intervention must be registered as a medical device and must be regulated by the MHRA for use in the UK. The evidence-based therapeutic intervention must be compliant with the Digital Technology Assessment Criteria (DTAC).Sub-Category 26.1 – Digital cognitive behavioural therapy for adults with insomniaAn evidence-based therapeutic intervention delivered through software to prevent, manage, or treat insomnia and insomnia symptoms. This intervention will be accessed via a smartphone app or online and engage the patient without the involvement of a clinician. The evidence-based therapeutic intervention must be registered as a medical device and must be regulated by the MHRA for use in the UK. The evidence-based therapeutic intervention must have proprietary Randomised Controlled Trial evidence that demonstrates safety and efficacy.The evidence-based therapeutic intervention must be compliant with the Digital Technology Assessment Criteria (DTAC).